NEW DRUG DISCOVERY PROJECT

新药发现项目

• 批准号: 3939582
• 负责人: B S KRAMER
• 金额: --
• 依托单位: DIVISION OF CANCER TREATMENT
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3939582
• 关键词: antileukemic agent; antineoplastics; carcinoma; drug design /synthesis /production; drug screening /evaluation; human tissue; lung neoplasms; lymphocytic leukemia; monoclonal antibody; mycosis fungoides lymphoma; neoplasm /cancer chemotherapy; neoplasm /cancer radionuclide therapy; yttrium

The primary goal of this group is to identify new agents of potential clinical use in treating solid tumors. A. major effort over the past year has been in the validation of a new in vitro assay which may be helpful as a preclinical screening model for antitumor agents. The model has been used to predict the clinical activity of 7 chemotherapeutic agents against 11 human colorectal carcinoma cell lines which have been developed in this branch. At present, the predictions made from this in vitro model are being validated in a nude mouse xenograft in vivo model. Since the NCI screening program for new agents is based upon this preclinical in vitro assay, it will be very important to validate the results in an in vivo system. At present, we are involved in several trials of new experimental therapeutic agents: Dihydrolenperone in lung cancer; a radiolabeled monoclonal antibody (90yttrium-T101) in mycosis fungoides and chronic lymphocytic leukemia. We also plan a trial of 4-ipomeanol in lung cancer and a trial of yttrium- labelled anti-CEA monoclonal antibody in colon cancer.

该小组的主要目标是确定 在治疗实体瘤中的潜在临床用途。 A.重大努力 在过去的一年中，一直在验证新的体外 作为临床前筛选模型可能有用的测定 抗肿瘤剂。 该模型已用于预测 7种化学治疗剂对11人的临床活性 在此开发的结直肠癌细胞系 分支。 目前，由此体外做出的预测 在体内裸鼠异种移植物中正在验证模型 模型。 由于新代理的NCI筛选程序是基于的 在这种临床前的体外测定中，对于 验证体内系统中的结果。 目前，我们参与了几项新实验试验 治疗剂：肺癌中的二氢烯烃；一个 放射性标记的单克隆抗体（90yttrium-t101） Fungoides和慢性淋巴细胞性白血病。 我们还计划一个 肺癌中4- ipomeanol的试验和Yttrium-试验 结肠癌中标记的抗CEA单克隆抗体。